Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal

Journal of Surgical Oncology

Volumn 107, Issue 4, 2013, Pages 422-427

  Wang, Quanrongzi ^a,b   Yu, Tongfu ^a   Yuan, Yifeng ^b   Zhuang, Haiwen ^b   Wang, Zhaojing ^b   Liu, Xisheng ^a   Feng, Min ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

hepatocellular carcinoma; regulatory T cells; sorafenib; TGF

Indexed keywords

SORAFENIB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILD PUGH SCORE; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HEMANGIOMA; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER CYST; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874251938     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23227     Document Type: Article

References (29)

1. Dhanasekaran R, Kooby DA, Staley CA, et al.: Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480.
2. Chen G, Lin W, Shen F, et al.: Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803.
3. Gao Q, Qiu SJ, Fan J, et al.: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
4. Fu J, Xu D, Liu Z, et al.: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
5. Wang ZK, Yang B, Liu H, et al.: Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 2011; 61: 911-916.
6. Perrone G, Ruffini PA, Catalano V, et al.: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44: 1875-1882.
7. Yang XH, Yamagiwa S, Ichida T, et al.: Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45: 254-262.
8. Ormandy LA, Hillemann T, Wedemeyer H, et al.: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464.
9. Hong H, Gu Y, Zhang H, et al.: Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol 2010; 159: 93-99.
10. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
11. Desar IM, Jacobs JFM, Hulsbergen-vandeKaa CA, et al.: Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011; 129: 507-512.
12. Chen YL, Lv J, Ye XL, et al.: Sorafenib inhibits transforming growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2011; 53: 1708-1718.
13. Lu L, Ma J, Wang X, et al.: Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol 2010; 40: 142-152.
14. Kudo M, Chung H, Haji S, et al.: Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
15. Jiang R, Tan Z, Deng L, et al.: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-909.
16. Cao M, Cabrera R, Xu Y, et al.: Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest 2007; 87: 582-590.
17. Feng M, Wang Q, Zhang F, et al.: Ex vivo induced regulatory T cells regulate inflammatory response of Kupffer cells by TGF-beta and attenuate liver ischemia reperfusion injury. Int Immunopharmacol 2012; 12: 189-196.
18. Lu L, Wang J, Zhang F, et al.: Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J Immunol 2010; 184: 4295-4306.
19. Feng M, Li G, Yuan Y, et al.: IL-17A-producing NK cells were implicated in liver injury induced by ischemia and reperfusion. Int Immunopharmacol 2012; 13: 135-140.
20. Molhoek KR, McSkimming CC, Olson WC, et al.: Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009; 58: 867-876.
21. Benson MJ, Pino-Lagos K, Rosemblatt M, et al.: All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 1765-1774.
22. Curiel TJ, Coukos G, Zou L, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
23. Matsuzaki K, Murata M, Yoshida K, et al.: Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48-57.
24. Ji GZ, Wang XH, Miao L, et al.: Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12: 644-648.
25. Gambichler T, Skrygan M, Kaczmarczyk JM, et al.: Increased expression of TGF-beta/Smad proteins in basal cell carcinoma. Eur J Med Res 2007; 12: 509-514.
26. Schmitz KJ, Wohlschlaeger J, Lang H, et al.: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.
27. Das M, Garlick DS, Greiner DL, et al.: The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011; 25: 634-645.
28. Tsukamoto H, Irie A, Senju S, et al.: B-Raf-mediated signaling pathway regulates T cell development. Eur J Immunol 2008; 38: 518-527.
29. Puente LG, He JS, Ostergaard HL:, A novel PKC regulates ERK activation and degranulation of cytotoxic T lymphocytes: Plasticity in PKC regulation of ERK. Eur J Immunol 2006; 36: 1009-1018.